Skip to main content
LB PHARMACEUTICALS INC logo

LB PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LBRX ISIN · US50180M1080 US Manufacturing
Filings indexed 88 across all filing types
Latest filing 2025-11-12 Regulatory Filings
Country US United States of America
Listing US LBRX

About LB PHARMACEUTICALS INC

https://lbpharma.us/

LB Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neuropsychiatric diseases, with a primary emphasis on schizophrenia and bipolar depression. The company's pipeline is centered on its lead product candidate, LB-102, an oral small molecule. LB-102 is being developed as a potential first-in-class benzamide antipsychotic for approval in the United States. The company is advancing LB-102 through late-stage clinical development, including a Phase III trial for schizophrenia and a Phase II study for bipolar depression, to address significant unmet needs in mental healthcare.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2025-11-12 English
10-Q
Interim / Quarterly Report Q3 2025
2025-11-06 English
8-K
Regulatory Filings
2025-11-06 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-10-17 English
Director's Dealing 2025
Director's Dealing
2025-09-30 English
Director's Dealing 2025
Director's Dealing
2025-09-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.